NovaPlex HPV28

The Centers for Disease Control and Prevention (CDC) plans to award a sole source purchase order to Seegene USA, Inc. for the provision of Novaplex HPV28 Detection Laboratory Tests. This procurement is authorized under FAR part 13.103-1, which permits a simplified acquisition procedure without competitive bidding. The contract's focus is to secure HPV28 laboratory testing services critical for CDC’s public health initiatives. Although this is not a competitive solicitation, the CDC invites other firms capable of providing the required services to notify the Contracting Officer within 10 days of the notice publication; such responses will be reviewed solely to determine whether a competitive procurement should be pursued, with the government retaining full discretion on this decision. The contract references solicitation number 2026-95234, posted on March 5, 2026, with a response deadline of March 15, 2026. The work is managed under the CDC Office of Acquisition Services, part of the Department of Health and Human Services, with performance expected in Georgia. The North American Industry Classification System code for this contract is 54138, indicating professional scientific and technical services. Points of contact are Phil Alexander and Steve Lester, who are available for inquiries related to this acquisition. This contracting action underscores the government’s intent to expedite access to crucial diagnostic testing supplies by leveraging a sole source procurement process.